Recent news coverage includes general market and economic topics unrelated to RetinalGenix’s business, with no new company-specific developments reported in the latest news cycle.

• No recent company-specific news developments were reported in the primary business news sources as of May 20, 2026, with coverage focused on broader market and economic topics such as crude oil prices, AI developments, and stock market movements [N1][N2][N3][N4][N5][N6][N7][N8].

RetinalGenix’s integrated platform combining genetic testing, retinal imaging, and a secure AI-driven patient database could address significant unmet needs in early detection and monitoring of eye and systemic diseases. The planned launch of genetic test kits and the RetinalCam™ device may enable accessible, cost-effective screening and monitoring outside traditional clinical settings. The company’s pharmaceutical candidates targeting dry AMD and Alzheimer’s syndrome represent potential therapeutic advances. Strategic collaborations and clinical studies may support product validation and future commercialization. The patient-controlled data approach could empower personalized healthcare and facilitate drug development [S1].

RetinalGenix has no approved products or revenue and faces substantial liquidity constraints with current cash insufficient to cover liabilities, raising doubt about its ability to continue as a going concern. Product development and commercialization timelines are uncertain and dependent on additional funding, which may not be available on favorable terms or at all. The company faces significant competition from larger, established players with greater resources. Regulatory, reimbursement, and market acceptance risks are material. Internal control weaknesses and management turnover add operational risks. Failure to secure adequate financing or achieve product market acceptance could force delays, reductions, or termination of operations [S1][S2].

RetinalGenix’s moat is based on its integrated approach combining genetic testing, retinal imaging, patient-controlled data management, and pharmaceutical therapies targeting ocular and systemic diseases. Its proprietary technologies include the RetinalCam™ device designed for economical home use without pupil dilation, and the RECAD™ AI database that anonymizes and securely manages patient genetic and imaging data. The acquisition of DNA/GPS Inc. adds pharmacogenetic mapping capabilities. The company’s focus on early detection and personalized medicine, combined with its patent portfolio and strategic collaborations, may provide competitive advantages. However, the company operates in a highly competitive and rapidly evolving medical technology and pharmaceutical landscape with larger, better-funded competitors [S1].

• Liquidity and Going Concern Risk: As of March 31, 2026, the company had only $44,000 in cash and current liabilities of approximately $2.56 million, with substantial doubt about its ability to continue as a going concern without additional funding.
• No Revenue and Profitability Uncertainty: The company has not generated any revenue from product sales and expects to operate at a net loss for the foreseeable future, with uncertain timing and likelihood of achieving profitability.
• Product Development and Commercialization Risk: Product launches depend on successful development, regulatory clearance, and market acceptance. Delays or failures could adversely impact the business.
• Competition: The company faces competition from larger, better-funded companies with established products and distribution networks in ophthalmic and pharmaceutical markets.
• Internal Control Weaknesses: Management has identified material weaknesses in internal controls over financial reporting due to lack of segregation of duties, which may affect financial statement accuracy.
• Dependence on Key Personnel: The company relies heavily on its CEO and key executives, with potential adverse effects if they depart or are unable to perform.
• Regulatory and Reimbursement Risks: Uncertainty exists regarding regulatory approvals and reimbursement levels, which could affect product pricing, market acceptance, and profitability.

• RetinalGenix Technologies Inc. is an ophthalmic research and development company focused on technologies to screen, provide information, and treat eye health disorders including sight-threatening diseases.
• The company’s mission is to improve patients' lives by providing critical information to treat eye diseases and other general health conditions.
• The business model is built on four strategic pillars: genetic testing, retinal imaging, patient informational database, and pharmaceutical therapies.
• Genetic testing products, including GPS oral swab tests, are planned for launch in late 2026, with a second genetic test for wet AMD responders targeted for 2027.
• The Retinal Imaging Platform includes the RetinalCam™, a portable retinal imaging device for home and remote monitoring, planned for beta testing in 2026 and potential commercialization in 2027.
• The Patient Informational Database (RECAD™ AI system) is being developed to securely combine patient genetic and imaging data anonymously, controlled by patients.
• Pharmaceutical therapies under development include RTG-2023 for dry age-related macular degeneration and RTG-2024 for Alzheimer’s syndrome dementia, subject to funding.
• The company has no products approved for sale and has not generated revenue from product sales to date.
• Operations have been funded primarily through private placements of common stock, with recent capital raises noted in 2024 and 2025.
• As of March 31, 2026, the company had cash and equivalents of $44,000 and current assets of $180,000, with current liabilities of approximately $2.56 million, resulting in liquidity ratios near zero.
• The company reported a net loss of $590,489 and basic and diluted EPS of -$0.03 for the quarter ended March 31, 2026.
• There is substantial doubt about the company’s ability to continue as a going concern due to limited cash resources and high liabilities.
• The company is conducting a clinical study with Pearl IRB to personalize medical evaluations for wet macular degeneration patients, enrolling up to 100 patients in 2026.
• RetinalGenix acquired DNA/GPS Inc. in 2022 to develop pharmacogenetic mapping and testing capabilities.
• The RetinalCam™ device does not require pupil dilation and is designed for economical home use with real-time physician alerting.
• The company does not expect the RetinalCam™ to require FDA approval as it is intended for screening and monitoring.
• The RECAD™ AI database aims to provide secure, anonymized patient data to facilitate early detection of ocular and systemic diseases and support drug development.
• The company faces risks including the need for substantial additional funding, uncertainty of product commercialization, competition, regulatory challenges, and internal control weaknesses.
• Management has identified material weaknesses in internal controls over financial reporting due to lack of segregation of duties.
• The company’s executive officers and principal stockholders control approximately 79% of outstanding shares, potentially influencing corporate decisions.